Aclacinomycin A

Short Summary : Topoisomerase I and II inhibitor

Category : Ubiquitination/ Proteasome|Proteasome

Purity : 0.98

CAS Number : 57576-44-0

Formula : C42H53NO15

Molecular Weight : 811.87

SMILE : OC1=CC=CC(C(C2=C3C(O)=C4C([C@@H](C(OC)=O)[C@@](O)(CC)C[C@@H]4O[C@H]5C[C@H](N(C)C)[C@H](O[C@@H]6O[C@@H](C)[C@@H](O[C@@H]7O[C@@H](C)C(CC7)=O)[C@@H](O)C6)[C@H](C)O5)=C2)=O)=C1C3=O

Solubility : Soluble in DMSO

Storage : Store at -20°C

Description : Aclacinomycin A is a dual inhibitor of topoisomerase I and II [1]. Aclacinomycin A is an anticancer drug which can reduce the tumor with minimal damage to normal cells. Aclacinomycin A shows potency against a wide variety of solid tumours and haematological malignancies. In A549, HepG2 and MCF-7 cells, Aclacinomycin A shows cytotoxic activity with IC50 values of 0.27M, 0.32M and 0.62M, respectively. Aclacinomycin A induces cell apoptosis in these cells and the effects change to be necrosis when the incubation time is prolonged. Aclacinomycin A is demonstrated to increase the activity of both caspase-3 and caspase-8, thus inducing the activation of PARP. Apart from that, as an inhibitor of opoisomerases, Aclacinomycin A is found to induce DNA damage in V79 and irs-2 cells. Aclacinomycin A is used to treat acute leukaemias, lymphomas and other solid tumors through its inhibition of topo II [1, 2].References:[1] Hajji N, Mateos S, Pastor N, Domnguez I, Corts F. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res. 2005 May 2;583(1):26-35.[2] Rogalska A, Szwed M, J wiak Z. Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. Mutat Res. 2010 Jul 19;700(1-2):1-10.

Download datasheet